Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MT-ND6 pseudogene 12 (MTND6P12) is catalogued as a mitochondrial pseudogene corresponding to the **NADH:ubiquinone oxidoreductase core subunit 6 (ND6)** gene. Pseudogenes are DNA sequences derived from functional genes that have lost their protein-coding ability due to mutations; they are transcribed and/or translated only rarely, if at all. MTND6P12 does **not produce a functional ND6 protein** and is not involved in mitochondrial electron transport or oxidative phosphorylation like the canonical MT-ND6 gene[1][2]. There is no evidence this pseudogene plays a role as a drug target, biomarker, or is involved in any known diseases. **Key points:** - "MT-ND6 pseudogene 12" is not a functional gene, protein, enzyme, receptor, transporter, or recognized therapeutic target. - It lacks biological function or disease relevance distinct from the functional MT-ND6 gene. - No drugs target, and no mechanisms of action, biomarkers, or therapeutic modalities are associated. - If presented as a therapeutic target or protein-coding gene, this would be inaccurate. The entry likely exists for genomic annotation and comparison, not active biology or pharmacology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MT-ND6 pseudogene 12 (MTND6P12).